SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic therapies in patients with type 2 diabetes mellitus and are associated with improved glycaemic control as well as with reductions in body mass and blood pressure. In large cardiovascular outcome trials in patients with diab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews cardiology 2020-12, Vol.17 (12), p.761-772
Hauptverfasser:	Cowie, Martin R., Fisher, Miles
Format:	Artikel
Sprache:	eng
Schlagworte:	692/163/2743/137/773 692/699/75 692/700/565/1436 Antidiabetics Blood pressure Cardiac Imaging Cardiac Surgery Cardiology Cardiovascular diseases Cardiovascular Diseases - drug therapy Cardiovascular research Diabetes Drug therapy Ejection fraction Glucose metabolism Glycemic Control Heart failure Humans Hypoglycemic agents Medicine Medicine & Public Health Review Article Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!